Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBLFPN)

• Drug Name: IK-007 Drug Info
• Synonyms: grapiprant

Indication

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25	Phase 1/2	[1]

• Cross-matching ID: TTD Drug ID: DMBLFPN

Molecule-Related Drug Atlas

Drug(s) Targeting Prostaglandin E2 receptor EP4 (PTGER4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
16,16-dimethyl-PGE2	DMNF38S	Stem cell engraftment	QB63.8	Phase 2	[3]
RQ-00000007 (oral)	DMMYTRU	Pain	MG30-MG3Z	Phase 2	[4]
ONO-AE1-437	DMCUGI8	Asthma	CA23	Phase 2	[5]
BGC-20-1531	DMS2MQ5	Migraine	8A80	Phase 2	[6]
TPST-1495	DM3GSB2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
E7046	DMFVT43	Rectal adenocarcinoma	2B92	Phase 1	[8]
ONO-4232	DMO4SD2	Acute heart failure	BD10-BD13	Phase 1	[9]
ONO-4578	DME63VK	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
AN0025	DMGSYPY	Aggressive cancer	2A00-2F9Z	Phase 1	[10]
PGF2alpha	DM4XAU7	Solid tumour/cancer	2A00-2F9Z	Clinical trial	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostaglandin E2 receptor EP4 (PTGER4)	TT79WV3	PE2R4_HUMAN	Antagonist	[2]

References

• [1] ClinicalTrials.gov (NCT03696212) Open Label, Single Arm, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination With Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma. U.S.National Institutes of Health.
• [2] Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation. Vet Med Sci. 2015 Dec 21;2(1):3-9.
• [3] Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
• [4] Clinical pipeline report, company report or official report of Avarx.
• [5] An EP4 receptor agonist prevents indomethacin-induced closure of rat ductus arteriosus in vivo. Pediatr Res. 2004 Oct;56(4):586-90.
• [6] BGC20-1531, a novel, potent and selective prostanoid EP4 receptor antagonist: a putative new treatment for migraine headache. Br J Pharmacol. 2009 January; 156(2): 316-327.
• [7] Clinical pipeline report, company report or official report of Tempest Therapeutics.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] ONO-4232, an EP4-selective Agonist, Improves Left Ventricular Diastolic Dysfunction and Ameliorates Acute and Chronic Heart Failure in Animal Models. Circulation. 2012; 126: A15345.
• [10] AN0025, a novel antagonist of PGE2-receptor E-type 4 (EP4), in combination with total neoadjuvant treatment of advanced rectal cancer. Radiother Oncol. 2023 Aug;185:109669.
• [11] Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41.